Roberts Glore & CO Inc Astrazeneca PLC Transaction History

Roberts Glore & CO Inc

$354 Million
Q3 2025

A detailed history of Roberts Glore & CO Inc transactions in Astrazeneca PLC stock. As of the latest transaction made, Roberts Glore & CO Inc holds 3,206 shares of AZN stock, worth $286,616. This represents 0.07% of its overall portfolio holdings.

Number of Shares

3,206

Previous 3,240 1.05%

Holding current value

$286,616

Previous $226,000 8.41%

% of portfolio

0.07%

Previous 0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	SELL	$68.72 - $82.11 $2,336 - $2,791	-34 Reduced 1.05%	3,206 $245,000
Q2 2025 Aug 07, 2025	SELL	$64.87 - $75.0 $123,836 - $143,175	-1,909 Reduced 37.08%	3,240 $226,000
Q4 2024 Feb 07, 2025	BUY	$63.2 - $79.58 $31,789 - $40,028	503 Added 10.83%	5,149 $337,000
Q2 2024 Aug 14, 2024	SELL	$66.81 - $80.83 $8,885 - $10,750	-133 Reduced 2.78%	4,646 $362,000
Q2 2023 Aug 14, 2023	SELL	$69.91 - $75.81 $16,079 - $17,436	-230 Reduced 4.59%	4,779 $342,000

Q1 2023 May 08, 2023	BUY	$63.15 - $71.6 $4,736 - $5,370	75 Added 1.52%	5,009 $347,000
Q4 2022 Feb 13, 2023	SELL	$54.21 - $70.44 $20,111 - $26,133	-371 Reduced 6.99%	4,934 $334,000
Q3 2022 Nov 07, 2022	SELL	$53.02 - $135.75 $28,736 - $73,576	-542 Reduced 9.27%	5,305 $291,000
Q2 2022 Aug 11, 2022	SELL	$59.26 - $71.14 $14,459 - $17,358	-244 Reduced 4.01%	5,847 $386,000
Q1 2022 May 02, 2022	SELL	$55.72 - $67.12 $108,431 - $130,615	-1,946 Reduced 24.21%	6,091 $404,000
Q4 2021 Feb 11, 2022	BUY	$54.02 - $63.83 $5,239 - $6,191	97 Added 1.22%	8,037 $468,000
Q3 2021 Nov 12, 2021	BUY	$55.56 - $60.79 $441,146 - $482,672	7,940 New	7,940 $477,000

Others Institutions Holding AZN

# of Institutions

1,501

Shares Held

500M

Call Options Held

5.59M

Put Options Held

3.18M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $277B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Roberts Glore & CO Inc , based on Form 13F filings with the SEC.

News

Stay updated on Roberts Glore & CO Inc with notifications on news.

Account

Roberts Glore & CO Inc Astrazeneca PLC Transaction History